SCHEMBL10219856

SCHEMBL10219856

CCC(=S)NCCn1c(C)nc2cc(-c3nc4ccccc4o3)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.43
▸ HSD17B10 Q99714 5/20 0.43
▸ ALDH1A1 P00352 5/20 0.42
▸ NPC1 O15118 5/20 0.42
▸ RAB9A P51151 5/20 0.42
▸ HPGD P15428 4/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ HCRTR1 O43613 2/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ STAT1 P42224 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42
▸ TSHR P16473 3/20 0.42
▸ USP2 O75604 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ XBP1 P17861 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ MAPT P10636 3/20 0.39
▸ BCHE P06276 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686320 0.89 ALDH1A1 (0.44) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL2686523 0.83 KDM4E (0.48) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL2688545 0.83 MAPT (0.51) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL2688624 0.82 KMT2A (0.53) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL2687585 0.82 SMN1; SMN2 (0.46) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL2686316 0.82 KDM4E (0.41) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL2688141 0.81 BRD4 (0.46) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL2687005 0.81 KDM4E (0.47) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL2687383 0.81 KDM4E (0.55) KDM4EHSD17B10ALDH1A1NPC1RAB9A
SCHEMBL10219624 0.80 NPC1 (0.49) KDM4EHSD17B10ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 KDM4E 4538/4885HSD17B10 1939/4885ALDH1A1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback